Lyophilization Serves as an Effective Strategy for Drug Development of the α9α10 Nicotinic Acetylcholine Receptor Antagonist α-Conotoxin GeXIVA[1,2]
Sign Up to like & getrecommendations! Published in 2021 at "Marine Drugs"
DOI: 10.3390/md19030121
Abstract: α-Conotoxin GeXIVA[1,2] is a highly potent and selective antagonist of the α9α10 nicotinic acetylcholine receptor (nAChR) subtype. It has the advantages of strong efficacy, no tolerance, and no effect on motor function, which has been… read more here.
Keywords: drug development; conotoxin gexiva; gexiva; nicotinic acetylcholine ... See more keywords
Novel αO-conotoxin GeXIVA[1,2] Nonaddictive Analgesic with Pharmacokinetic Modelling-Based Mechanistic Assessment
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14091789
Abstract: αO-conotoxin GeXIVA[1,2] was isolated in our laboratory from Conus generalis, a snail native to the South China Sea, and is a novel, nonaddictive, intramuscularly administered analgesic targeting the α9α10 nicotinic acetylcholine receptor (nAChR) with an… read more here.
Keywords: pharmacokinetic modelling; conotoxin; conotoxin gexiva; mechanistic assessment ... See more keywords